CHEK1 and cancer: Finally, we note that, because Chk1 inhibitors are being assessed as anti-cancer agents [51], understanding the repertoire and functional consequences of Chk1-mediated phosphorylations might suggest how Chk1 inhibitors can be best exploited clinically.